Will Beta

Main Menu

  • Volatility
  • Systematic Risk
  • Returns Of Assets
  • Beta Data
  • Finance Debt

Will Beta

Header Banner

Will Beta

  • Volatility
  • Systematic Risk
  • Returns Of Assets
  • Beta Data
  • Finance Debt
Systematic Risk
Home›Systematic Risk›Journal for Managed Care & Specialty Pharmacy Publishes Research Papers in January 2022 Issue

Journal for Managed Care & Specialty Pharmacy Publishes Research Papers in January 2022 Issue

By Rogers Jennifer
December 25, 2021
0
0


ALEXANDRIE, Virginia, December 24 – The Managed Care Journal and Specialty pharmacy, a peer-reviewed journal that claims to strive to engage and serve professionals in pharmacy, medicine, nursing and allied fields to maximize the value of pharmaceuticals and pharmaceutical services provided to patients of Managed Care Pharmacy Academy, has published research articles on the following topics in his January 2022 editing:

To research:

* Trend and effects of high-deductible health insurance plans in the health system: problems of financial access in the management of cognitive disorders

* Biological monitoring to reduce drug-related adverse events: a mixed-method study

* Real-world analysis of churn rate among young adults with schizophrenia using the Colorado All Payors Claims Database

Advertising

* Coverage of genetic therapies for spinal muscular atrophy in paid Medicaid programs

* Economic impact of the application of the simplified treatment algorithm AASLD-IDSA on the actual management of hepatitis C

* Application of a diazepam milligram equivalence algorithm to assess the intensity of the benzodiazepine dose in Rhode Island in 2018

Research paper :

* US Healthcare Utilization and Costs in Adult Atopic Dermatitis Patients by Disease Severity

* Performance-based risk sharing agreements for devices and diagnostics in United States: a systematic review

* Pharmacists as Accessible Health Care Providers: Quantifying the Opportunity

Outlook on value:

* JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: efficacy and benefit

* The efficacy and value of eculizumab and efgartigimod for generalized myasthenia gravis

the January 2022 edition of the Journal for Managed Care and Specialty Pharmacy can be viewed at https://www.jmcp.org/toc/jmcsp/28/1.


Related posts:

  1. ACMG clinical practice resource to help guide the clinical management of patients at increased risk for breast, pancreatic and ovarian cancer
  2. Manage water-related risks – on site and in the watershed
  3. HEARD AT HALFTIME: WHO’s Ryan explains Olympic virus risk; sprint star Richardson ready to protest? More on DK Metcalf, but not track & field
  4. IoT-based access control device vulnerabilities put users and providers at risk
Tagsunited states

Recent Posts

  • “Mathematics does not account for human emotions” – News Bitcoin News
  • Economic daily: the role of real estate in stabilizing the economy is emerging
  • ‘Race against time’ to sell Slough properties and land
  • Organic Asparagus Market Size and Forecast to 2028 | Altar Produce, DanPer, Beta SA, AEI, Agrizar – Designer Women
  • SoFi Technologies (NASDAQ:SOFI) vs Northern Lights Acquisition (NASDAQ:NLIT) Direct Survey

Archives

  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021

Categories

  • Beta Data
  • Finance Debt
  • Returns Of Assets
  • Systematic Risk
  • Volatility
  • Terms and Conditions
  • Privacy Policy